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Objectives:  The  aim of the  study  was  to examine  the hypothesis  that  MMR  exposure  has  a  negative
inﬂuence  on cognitive  development  in  children.  Furthermore,  MMR  was  compared  to  single measles
vaccine  to  determine  the  potential  difference  of  these  vaccines  safety  regarding  children’s  cognitive
development.
Methods:  The  prospective  birth  cohort  study  with  sample  consisted  of 369  infants  born  in  Krakow.  Vacci-
nation  history  against  measles  (date  and  the  type  of  the  vaccine)  was  extracted  from  physicians’  records.
Child  development  was  assessed  using the  Bayley  Scales  of  Infant  Development  (BSID-II)  up  to  3rd  year
of  life,  Raven  test  in  5th  and  8th year  and  Wechsler  (WISC-R)  in  6th  and  7th year.  Data  on  possible  con-
founders  came  from  mothers’  interview,  medical  records  and  analyses  of lead  and  mercury  level  at  birth
and  at  the  end  of  5th  year  of  life.  Linear  and  logistic  regression  models  adjusted  for  potential  confounders
were  used  to assess  the  association.
Results: No  signiﬁcant  differences  in  cognitive  and intelligence  tests  results  were observed  between
children  vaccinated  with  MMR  and  those  not  vaccinated  up to the  end  of the  2nd  year  of life. Chil-
dren  vaccinated  with  MMR  had  signiﬁcantly  higher  Mental  BSID-II  Index  (MDI)  in the 36th month  than
those  vaccinated  with  single  measles  vaccine  (103.8  ±  10.3  vs. 97.2 ± 11.2,  p = 0.004).  Neither  results  of
Raven  test  nor  WISC-R  were  signiﬁcantly  different  between  groups  of  children  vaccinated  with  MMR
and  with  single  measles  vaccine.  After standardization  to child’s  gender,  maternal  education,  family  eco-
nomical  status,  maternal  IQ, birth order  and  passive  smoking  all  developmental  tests  were  statistically
insigniﬁcant.
Conclusion:  The  results  suggest  that  there  is no  relationship  between  MMR  exposure  and  children’s  cog-
nitive  development.  Furthermore,  the  safety  of  triple  MMR  is the  same  as the single  measles  vaccine  with
respect  to cognitive  development.
.. Introduction
Despite the fact that a number of epidemiological studies failed
o show any association between MMR  vaccine and autism, the
ontroversy over the vaccine safety still exists [1–3]. The anti-
accine organizations and websites that portray themselves as
fﬁcial resources for credible data on vaccines continue to provide
awed or biased information about MMR  [4,5]. It serves to fuel pub-
ic concern regarding the safety of MMR  which leads to increased
ates of immunization refusal or delays on-time vaccination, and
onsequently causes a signiﬁcant risk of outbreaks of measles in
any European countries and the United States [6–8].
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To counter these anti-vaccination advocates and to promote
greater acceptance of vaccination (not exclusively MMR)  the
evidence-based information concerning the beneﬁts and the risk
of immunization is required [9–12]. The hypothesis that MMR  as
a triple live vaccine is more detrimental for children’s neurodevel-
opment in comparison to single measles vaccine was  developed in
the past [13–15]. Nevertheless, the studies have not provided evi-
dence against MMR  immunization [16–24]. While earlier studies
focused on more advanced health problems like autism [18,21,22],
currently epidemiological studies look for more subtle neurode-
velopmental outcomes that could be potentially linked to vaccines
exposure. Those can be detected by psychological tests being suf-
ﬁciently sensitive to monitor even minor, subclinical disorders
in children. Additionally essential is inclusion of a wide range of
Open access under CC BY-NC-ND licensepotential confounders that may  have an impact on children’s neu-
rodevelopment, like maternal age, education and IQ, mercury and
lead exposure during pregnancy and other prenatal and postnatal
factors.
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During the last years in Poland there was a good opportunity
o conduct the studies on the MMR  safety because the popula-
ion of children was diversiﬁed in terms of vaccination history
gainst measles. The part of infants was vaccinated with MMR
s a voluntary option (charged extra money) and some of them
ere vaccinated only with single measles vaccine which was  used
ccording to the national mandatory immunization schedule up to
004. Obviously, some children for different reasons have not been
accinated against measles at all.
The aim of this study was to examine the hypothesis that MMR
xposure has a negative inﬂuence on cognitive development in
hildren. Furthermore, MMR  was assessed in comparison to single
easles vaccine exposure, to determine the potential difference of
hese vaccines safety regarding children’s cognitive development.
.  Materials and methods
This  is a prospective cohort study, combining environmental
onitoring and molecular approaches with comprehensive neu-
odevelopment assessments. In the analysis we used data from
n earlier established Krakow birth cohort of children, being part
f ongoing, collaborative study with Columbia University in New
ork, on the vulnerability of fetus and child to environmental
actors. The study has received the approval of the Jagiellonian
niversity Ethical Committee.
The enrolment (November 3, 2000 – August 22, 2003) included
nly non-smoking women, aged 18–35 years, with singleton preg-
ancy without illicit drug use and HIV infection, free from chronic
iseases such as diabetes or hypertension and residing in Krakow
or at least one year prior to pregnancy. The infants were followed
p to 8th year of life. Each year mothers were asked to provide infor-
ation on infants’ health and household characteristics by trained
nterviewers, who carried out detailed, face-to-face standardized
nterviews. The Test of Nonverbal Intelligence, Third edition (TONI-3)
as administered to mothers. We  have included this instrument to
djust to the maternal contribution to child cognitive development.
.1. Vaccination data
The  data on infants’ vaccination history (date of vaccination and
ype of vaccine) were extracted from the physician’s records. The
accination status was based on measles vaccination during the
econd year of life.
.2.  Biological samples and analysis
Concentrations of cotinine and heavy metals (mercury, lead)
ere examined in Cord blood (at delivery) and capillary blood
5-year-old children). Whole blood lead concentrations were
etermined using inductively coupled plasma mass spectrometry
LIA’88 method “Blood lead cadmium mercury ICPMS ITB001A”.
his multi-element analytical technique is based on quadruple
CP-MS technology [25]. Mercury levels were measured at the
DC by Zeeman graphite furnace atomic absorption spectrome-
ry, using a phosphate/Triton X-100/nitric acid matrix modiﬁer.
old vapor atomic spectrometry following chemical reduction of
ercury compounds was used to measure total mercury in whole
lood. More details on blood sample collection and analysis were
resented in earlier publications [26,27].
.3. Infants neurodevelopment testingThe Fagan Test of Infant Intelligence (FTII) was conducted in
he 6th month of life. The Bayley Scales of Infants Development,
econd edition (BSID-II), was administered in the 12th, 24th and
6th months of life. The Mental Scale of that test includes itemsne 31 (2013) 2551– 2557
that  assess memory, habituation, problem solving, early num-
ber concepts, generalization, classiﬁcation, vocalization, language,
and social skills [28]. Test scores are adjusted to child’s age to
obtain the Mental Development Index (MDI). Test results are in
one of four categories: (1) accelerated performance (score > 115),
(2) within normal limits (score 85–114), (3) mildly delayed perfor-
mance (score 70–84), and (4) signiﬁcantly delayed (score < 69). The
outcomes range is from 50 to 150.
The test of Raven’s Colored Progressive Matrices (Raven) was
administered twice, in 5th and 8th year of life. The outcomes of
the test were measured in terms of centiles. Because the results of
this test were generally high, the cut point of poor result category
was 74th percentile, which means middle intelligence outcomes.
Output scale was  presented in centiles standardized to age groups.
The Wechsler Intelligence Scale for Children (WISC-R) was
administered in 6th and 7th year of life, and generated verbal, non-
verbal and total IQ for evaluated children. Category with IQ < 100
was considered as the poorer outcomes. The outcomes range is from
40 to 160.
All  neurodevelopment tests were conducted in the Depart-
ment of Epidemiology and Preventive Medicine by carefully trained
examiners being unaware of the child’s exposure. Bayley Scales as
well as Raven test both have well deﬁned criteria and were con-
sidered as fully consent between different examiners. In order to
provide fully comparable assessment of WISC-R test, one psychol-
ogist rated performed answers for all children.
2.4. Statistical analysis
In  the descriptive analysis, difference in the distribution of
women and newborns’ parameters grouped by measles vacci-
nation status were tested using 2 (for nominal variables) and
Mann–Whitney and Kruskal–Wallis tests (for continuous vari-
ables).
The comparison of the tests outcomes according to the exposure
to the type of vaccine (MMR  vs. monovalent vaccine and MMR  vs.
unvaccinated group) was studied using multivariate linear models.
As well the logistic models were used to assess risk of developmen-
tal delay (MDI < 85, Raven < 74, IQ < 100).
All variables from Table 1 which showed a probable association
with measles vaccination status (p < 0.1) were included in statisti-
cal multivariable models. Blood lead level at the age of 5 was  used
as confounder in models for 5-year-old and older children. Addi-
tionally, the child’s gender was  added to all models as it is highly
associated with developmental tests’ performance.
Statistical analyses were performed using STATA software ver-
sion 8.0.
3.  Results
3.1. Study population
The  analyzed population consisted of 369 children: 52.3% boys
and 47.7% girls. From that group 10 children (2.7%) were absent dur-
ing BSID-II test in 24th month. Retention rate in that group during
psychological tests in further years was respectively: 94.1% in 3rd,
72.6% in 5th, 58.5% in 6th, 60.2% in 7th and 51.2% in 8th. During the
second year of life (period of exposure included to analysis) 83.2%
of children were exposed to MMR,  8.7% to single measles vaccine
and 8.1% were unvaccinated. Only two children with known vacci-
nation history were non-vaccinated against measles up to the 6th
year of life.
Children vaccinated with MMR  were more frequently the ﬁrst
child in the family than those either vaccinated with monovalent
vaccine or unvaccinated up to the end of the 2nd year of life (69.7%,
D. Mrozek-Budzyn et al. / Vaccine 31 (2013) 2551– 2557 2553
Table  1
Cohort characteristics of children vaccinated and unvaccinated against measles up to 2nd year of life.
MMR  vaccine Monovalent vaccine Non-vaccinated p
N % N % N %
Child’s gender:
Boys  160 52.1 18 56.2 15 50.0 0.968
Girls  147 47.9 14  43.8 15  50.0
Maternal  education
Primary/vocational school 57 18.6 15 46.9 9 30.0 0.001
High  school 18 25.4 10 31.2 6 20.0
University  172 56.0 7 21.9 15 50.0
Maternal  marital status
married  290 94.5 30  93.8 28  93.3 0.730
not  married 17 5.5 2  6.2 2  6.7
Poor  economical status 18 5.9 6 18.8 4 13.3 0.016
Birth  order
1  214 69.7 9 28.1 10 33.3 <0.001
2  83 27.0 16 50.0 18 60.0
≥3  10 3.3 7 21.9 2 6.7
Birth  weight < 250 g 10 3.3 1 3.1 1 3.3 1.000
Gestational  age <37 weeks 15 4.9 0 – 3 10.0 0.148
Virus  infection during pregnancy 74 24.1 5 15.6 10 33.3 0.265
Passive  tobacco smoking during pregnancy
Non-exposed 231 75.2 11 34.4 20 66.7 <0.001
Up  to 5 cigarettes/day 57 18.6 11 34.4 3 10.0
Above  5 cigarettes/day 19 6.2 10 31.2 7 23.3
Cord  blood mercury level >0.9 g/L 107 46.5 9 42.9 10 43.5 0.920
Cord  blood lead level >1.2 g/L 143 51.3 18 62.1 15 53.6 0.536
Fish  consumption during pregnancy above 100 g per week 81 26.4 11 34.4 6 20.0 0.434
MMR vaccine Monovalent vaccine Non-vaccinated p
Mean SD Mean SD Mean SD
Mother’s age at 2nd trimester 27.7 3.5 27.7 4.5 27.7 3.8 0.971
Maternal  nonverbal intelligence (TONI-3) 109.3 16.8 101.0 18.2 110.3 22.8 0.091
Maternal  depression scale during pregnancy 27.4 0.6 28.0 2.5 28.8 2.3 0.811
Cord  blood mercury level (g/L) 1.08 0.05 0.95 0.13 1.01 0.15 0.561
Cord  blood lead level (g/L) 1.43 0.04 1.48 0.09 1.61 0.21 0.439
Blood  mercury level at age of 5 years (g/L) 0.57 0.32 0.52 0.23 0.44 0.26 0.438
Blood  lead level at age of 5 years (g/L) 2.16 0.78 2.53 0.70 2.27 0.65 0.063
Peak  blood mercury level (g/L) 1.09 0.68 0.88 0.57 0.99 0.68 0.133
Peak  blood lead level (g/L) 1.94 0.88 1.96 0.78 2.03 1.03 0.811
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8.1% and 33.3%, p < 0.001) (Table 1). Mothers of children vaccinated
ith monovalent vaccine had less frequently university degree
han those vaccinated with MMR  or unvaccinated (21.9%, 56.0%
nd 50%, p = 0.001) and were in higher percentage both in poor
conomical situation (18.8%, 5.9%, 13.3% respectively, p = 0.016)
nd exposed to passive tobacco smoking during pregnancy (65.6%,
4.8%, 33.3%, p < 0.001). No statistically signiﬁcant differences were
bserved in other variables taken into consideration (Table 1).
.2.  Children’s cognitive development in pre-exposure period
There  were no signiﬁcant differences in tests scores that were
erformed during pre-exposure period. The average outcomes of
he Fagan test, administered in the 6th month of life, amounted
o about 60 points in all three groups under analysis. The average
cores of MDI  in the 12th month of life were also on the simi-
ar level (from 98.3 to 102.7 point) (Fig. 1). In 1-year-old infants
ategories: “Mildly Delayed” or “Signiﬁcantly Delayed” (MDI < 85)
ere reached by about 10% of children and differences were not
tatistically signiﬁcant between studied groups (Table 3).
.3.  MMR  and cognitive tests outcomesNo signiﬁcant differences of cognitive and intelligence tests
esults were observed between children vaccinated with MMR
nd unvaccinated in univariable analysis. Their outcomes were on78.8 67.7 75.3 54.4 0.901
similar level (Fig. 1). After standardization to child’s gender, mater-
nal education, family economical status, maternal IQ, birth order
and passive tobacco smoking (as well as lead level in cord blood in
the end of 5th year of life for 5-year-old and older children) none of
the tests outcomes of cognitive development or intelligence tests
results were statistically signiﬁcant (Table 2).
Children vaccinated with MMR  had signiﬁcantly higher mental
BSID-II scores in the 36th month than those vaccinated with single
measles vaccine (103.8 ± 10.3 vs. 97.2 ± 11.2, p = 0.004) (Fig. 1). Nei-
ther results of Raven test nor WISC-R were signiﬁcantly different
between groups of children exposed to MMR  and single measles
vaccine. The results of MDI  in the 36th month in children vacci-
nated with MMR  vs. vaccinated with single measles vaccine became
non-signiﬁcant (  ˇ = 4.7, p = 0.056) after standardization to child’s
gender, maternal education, family economical status, maternal IQ,
birth order and passive tobacco smoking. Results of MDI  in the 24th
month as well as WISC-R and Raven in MMR  and monovalent group
didn’t differ signiﬁcantly.
Subjects  exposed to monovalent vaccine had a higher per-
centage of “Mildly Delayed” or “Signiﬁcantly Delayed” (MDI < 85)
outcomes in the 24th month and the 36th month of life in com-
parison with exposed to MMR  or unvaccinated children (26.7% vs.
8.2% and 11.1%, p = 0.009 and 20.7% vs. 3.5% and 4.1%, p = 0.023,
respectively). The differences between groups related to delayed
tests outcomes in children in the 5th, 6th, and 8th years of life
were not statistically signiﬁcant. The percentage of “delayed”
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Fig. 1. Average tests scores in MMR  or monovalent vaccine exposed and non-exposed groups (with standard deviation).
Table 2
Standardized test scores in MMR  and monovalent exposed and non-exposed groups (multivariable linear regression models).
Test Age MMR  vs. non-vaccinated MMR  vs. monovalent vaccine
a 95% CI p a 95% CI p
MDI  of BSID II 24th  month of life −3.7 −9.6; 2.1 0.212 1.0 −5.1; 7.0 0.749
MDI  of BSID II 36th month of life −3.4 −8.2; 1.5 0.172 4.7 −0.1; 9.5 0.056
Raven  (centilles) 5th year of life −3.0 −13.5; 7.5 0.574 3.1 −7.8; 14.0 0.572
WISC−R  6th year of life
Verbal  IQb −2.5 −11.1; 6.1 0.568 −3.5 −11.8; 4.7 0.394
Non−verbal  IQb −2.8 −11.1; 5.5 0.502 −0.3 −8.4; 7.7 0.936
IQb −3.0 −11.0; 5.1 0.464 −2.23 −10.1; 5.6 0.572
WISC-R  7th year of life
Verbal  IQb 3.5 −4.2; 11.2 0.370 −0.7 −9.6; 8.1 0.867
Non-verbal  IQb −0.9 −10.1; 8.2 0.843 3.4 −7.2; 14.1 0.523
IQb 1.5 −6.0; 9.1 0.688 1.3 −7.4; 10.1 0.761
Raven  (centilles)b 8th year of life −2.3 −13.9; 9.3 0.694 0 −12.8; 12.7 0.997
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Pa Standardized to child’s gender, maternal education, maternal IQ, maternal eco
obacco smoke during pregnancy(yes vs. no).
b Additional standardization to blood lead level at the age of 5.
erbal IQ results in 7 year-old children was signiﬁcantly higher in
roup vaccinated with monovalent vaccine compared to MMR  and
nvaccinated subjects (20% vs. 2.6% and 7.1%, p = 0.012) (Table 3).After  adjusting to possible confounders, MMR  exposure didn’t
ffect the risk of delayed cognitive development compared to nei-
her unvaccinated children nor those vaccinated with monovalent
easles vaccine. The odds ratio of delayed cognitive development
able 3
ercentage of children with mild or signiﬁcant developmental delay according to the test
MMR  
N % 
MDI  of BSID II 12th month of life 23 7.5 
MDI  of BSID II 24th month of life 24 8.2 
MDI  of BSID II 36th month of life 10 3.5 
Raven  (centilles) 5th year of life 44 19.3 
WISC-R  6th year of life
Verbal IQ 13 7.1 
Non-verbal  IQ 12 6.6 
IQ  10 5.5 
WISC-R  7th year of life
Verbal IQ 5 2.6 
Non-verbal  IQ 8 4.2 
IQ  8th year of life 5 2.6 
Raven  (centilles) 8th year of life 18 10.8 cal status, birth order (further child vs. ﬁrst one) and exposure to environmental
was  even signiﬁcantly lower in MMR  than in single measles vac-
cine group among 3-year-old children (OR = 0.18, 95%CI: 0.03–0.91)
(Table 4).In  children older than 6 year-old it was impossible to build
up logistic regression models due to the lack of subjects with
developmental delay in monovalent vaccine and unvaccinated
group.
s outcomes.
Non-vaccinated Monovalent vaccine p
N % N %
3 10.7 4 12.9 ns
3 11.1 8 26.7 0.009
1 4.2 6 20.7 0.003
5 26.3 7 35.0 ns
2 14.3 2 10.5 ns
2 14.3 2 10.5 ns
1 7.1 1 5.3 ns
1 7.1 3 20.0 0.012
0 0.0 1 6.7 ns
0 0.0 1 6.7 ns
0 0.0 0 0.0 ns
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Table  4
The  risk of delayed development in MMR  vs. monovalent vaccine exposed or non-exposed groups (multivariate logistic regression models).
Test Age MMR  vs. non-vaccinated MMR  vs. monovalent vaccine
OR 95% CI p OR 95% CI p
MDI  of BSID II b 24th month of life 1.35 0.15; 12.0 0.786 0.35 0.09; 1.37 0.132
MDI  of BSID II b 36th month of life 0.37 0.03; 4.02 0.414 0.18 0.03; 0.91 0.038
Raven  (centilles)a 5th year of life 1.22 0.23; 6.55 0.820 0.45 0.11; .1.81 0.261
WISC-R  6th year of life
Verbal  IQa 1.23 0.09; 17.03 0.875 – – –
Non-verbal  IQa – – – 1.04 0.09; 11.78 0.973
IQ  – – – – – –
OR standardized to child’s gender, maternal education, maternal IQ, maternal economical status, birth order (further child vs. ﬁrst one) and exposure to environmental
tobacco smoke during pregnancy (yes vs. no).
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b Standardization without maternal economical status.
. Discussion
The study addresses the association between MMR  and cog-
itive development in children during the eight-year observation
ince the exposure. Because the population of children under study
as diversiﬁed in terms of vaccination history, we concentrated
n the safety of MMR  vs. single measles vaccine. No other coun-
ry in Europe and the USA had similar opportunity to conduct
uch an analysis as MMR  vaccine was introduced there to the
mmunization calendar much earlier than in Poland, and single
easles vaccine has not been administered since over 20 years
here [29,30].
The  studies on the safety of both MMR  and single measles
accine and their link with the risk of cognitive development
isorders in children have signiﬁcant value, especially that the
rowing number of parents are opting out of the MMR  vacci-
ation or at least substituting it with a single vaccinations [31].
he result is that the MMR  vaccination rate has fallen, caus-
ng a signiﬁcant risk of outbreaks of measles in many countries
7,8]. Our ﬁndings are supporting commonly accepted immu-
ization program against measles and rubella which allows to
eplace single vaccines with MMR  vaccine, if adequately controlled
32].
The results of the studies published over the last 12 years on
he association between MMR  vaccine and autism and our obser-
ations have found no evidence for such causal links [17–24].
espite adverse opinions and pressures, the WHO  has not with-
rawn the recommendations for MMR  vaccine, and measles and
ubella prevention programs have been continued, though with
ome difﬁculties, being a part of the MMR  mass immunization
olicy [33].
The  study also deals with the association between MMR  immu-
ization and development of the vaccinated and unvaccinated
hildren, which was possible only in the early exposed infants, as
ome of the children from this cohort were vaccinated with delay,
ver the age of two. Having in mind potentially signiﬁcant role of
he time of exposure, we concentrated on the effects of different
accination status in children at the age of two. Until this age most
hildren in Poland became vaccinated according to the manda-
ory immunization program for preventing measles and rubella,
nd as many as 95% of children should have already received the
rst dose of MMR.  Therefore, the analysis of MMR  vaccine safety
elated to the infants exposure time is crucial for ﬁnding the link
etween the vaccination and child development. If there were no
vidence for the harmful effect of MMR  vaccine on the develop-
ent of early exposed infants, it would be hard to anticipate that
he children vaccinated with different time delays are at risk. In this
tudy authors have not concentrated on the causal link between
MR and autism although this hypothesis caused high level ofanxiety around the MMR  vaccine. There is sufﬁcient epidemiologic
evidence that failed to show any link between MMR  and autism
[17–23]. At generally low incidence rates of autism, we  should not
anticipate high rates of autism in a prospective study of the cohort
consisting of 500 children. During a few-year observation there
was only a single case of autism that corresponded to the over-
all average incidence of autism. Still, the size of the cohort was  big
enough to observe the dynamics of health outcomes, such as disor-
ders of cognitive development, psychomotor activity or behavior.
Assuming a power level 0.8 and  ˛ = 0.05 and the small number of
children unvaccinated or vaccinated with monovalent vaccine, our
population was  big enough to ﬁnd possible differences in neurode-
velopment outcomes, e.g. 6-point difference for MDI  outcomes or
8-point for WISCR IQ.
The main purpose of the study was to establish whether there
is an association between MMR  and early developmental delays of
milder intensity. This is the strong point of the study because most
of the epidemiologic analyses concentrate on the links between
MMR and more serious post -vaccination side effects in chil-
dren. In our opinion, the analyses should also cover those mild
side effects or disorders, to be able to either ﬁnd evidence for or
against the causal relationship between MMR  and other less seri-
ous health outcomes. Similar issues have not already been analyzed
in clinical studies conducted so far and epidemiological surveys
do not provide information on adverse post -vaccination effects
and their inﬂuence on child development. All developmental tests
conducted within the study provided consistent results that failed
to show any link between MMR  and increased risk of cognitive
development delays in children. The analyses of child develop-
ment over the period of several years also did not provide the
evidence for the association of tests scores and the type of expo-
sure, MMR  or single vaccine. The children vaccinated with MMR
had even slightly higher scores of infant development in BSID-II
tests in 24th and 36th month of life and in Raven at the age of
ﬁve. Higher scores obtained by the vaccinated children can in no
way link MMR  with higher intellectual outcomes, as this effect
is most likely associated with the parents’ education, intelligence
or material status. During the time of the study MMR  was  a rec-
ommended vaccine, though it was charged extra, and maybe for
this reason it was  chosen by better educated and well-off parents.
Therefore to avoid the bias, associated with social and economical
inequalities, we  included available factors such as maternal educa-
tion, marital status and family economical status in ﬁnal statistical
models.
Wakeﬁeld’s hypothesis stated that MMR  vaccine causes a series
of events including intestinal inﬂammation, loss of intestinal bar-
rier function, entrance into the bloodstream of encephalopathic
proteins and consequent development of autism [15]. Though it has
been challenged many times, there are still doubts as to MMR  safety
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n terms of child development [11,12]. We  estimate that our study
s the ﬁrst one that addresses MMR  safety in wider sense beyond
utism, and therefore it could be very considerable for public accep-
ance of immunization. The weak point of our research is that the
esults cannot be compared to any other ﬁndings reported in the
iterature. Only certain, limited number of quality categories can be
ompared and the results of these observations are compatible with
he ﬁndings of other authors in providing strong evidence against
ssociation between MMR  and developmental delay in children
ith autism [34].
An  important advantage of the study is that it compares
he results of developmental tests before MMR  exposure (two
ndependent tests assessing cognitive development in children
dministered in the 6th and 12th month of life) and after MMR
mmunization. No signs of cognitive developmental delay were
ound after MMR  exposure compared to children who received
ingle measles vaccines and those unvaccinated. All results of the
ifferent developmental tests used in the study were consistent.
he tests administered in our study are highly reliable and val-
dated, the methodology was carefully selected in all cases. The
tudy was blinded during the collection of questionnaires and
herefore the interpretation of the results was objective. Long
bservation period (8 years) further increased reliability of the
btained results.
The  study is a prospective cohort observation, which is the
ost powerful tool in terms of formulating conclusions. Study
esign covered assessment of multiple agents that might poten-
ially inﬂuence child development. Wide variety of available data
ade possible taking into consideration multiple potential con-
ounders, which is a great beneﬁt of the study. The obtained
esults had as well high level of internal agreement. No evi-
ence was found for the links between MMR  and developmental
elay in the children from the cohort. The great advantage of
he study is that it is at low risk of bias due to MMR  vac-
ine manufacturers. All MMR  vaccines have been registered for
he use in Poland and there was no preference for any of the
accines.
In conclusion, our results suggest that there is no relation-
hip between MMR  exposure and children cognitive development.
urthermore, the safety of triple MMR  is similar to single
easles vaccine with respect to cognitive development. How-
ver, as the results are of the ﬁrst epidemiological study regarding
hat issue, the interpretation of the effects requires careful
ssessment.
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